SBI-183 

SBI-183 is an orally active inhibitor of QSOX1 (K_d: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo ^[1].

SBI-183 (6.25-50 μM, 15 min) inhibits the enzymatic activity of rQSOX1 in a dose-dependent manner^[1].
SBI-183 inhibits proliferation of tumor cells, but does not kill fibroblasts or rapidly proliferating PBMC (0.625-20 μmol/L, 5 days), inhibits viability of 786-O, RCJ-41T2, and MDA-MB-231 with IC₅₀s of 4.6 μM, 3.9 μM, and 2.4 μM, respectively (0.076 nM-40 μM, 72 h)^[1].
SBI-183 (2.5-20 μM, 4-8 days) inhibits tumor invasion in both 2D and 3D models of 786-O, RCJ-41T2, MDA-MB-231, A549 and MIA PaCa₂ dose-dependently^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SBI-183 (786-O: 400 μg/mouse/day, p.o., 35 days; RCJ-41T2: 100 mg/kg, p.o., 21 days) inhibits tumor growth in two independent human xenograft mouse models of renal cell carcinoma^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

296.36

C₁₈H₂₀N₂O₂

625403-59-0

Solid

White to off-white

O=C(C1=CC(OC)=CC=C1)NC2=CC=C(N3CCCC3)C=C2

Room temperature in continental US; may vary elsewhere.

• [1]. Fifield, et al. Molecular Inhibitor of QSOX1 Suppresses Tumor Growth In Vivo. Molecular cancer therapeutics. 2020, 19(1), 112–122.  [Content Brief]